# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA4419934 | B | Inhibition of YAP1 (unknown origin) assessed as disruption in YAP1/OCT4 interaction by ELISA | Homo sapiens | 33 | ALA4419178 | single protein format | Patent Bioactivity Data | |
2. | ALA4419942 | B | Inhibition of YAP1 in human NCI-H1650 cells assessed as disruption in YAP1/OCT4 interaction at 5 uM incubated for 72 hrs by immunoprecipitation-Westem blot assay | Homo sapiens | 3 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
3. | ALA4419943 | B | Inhibition of YAP1 in human A549 cells assessed as disruption in YAP1/OCT4 interaction at 5 uM incubated for 72 hrs by immunoprecipitation-Westem blot assay | Homo sapiens | 3 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
4. | ALA4419954 | F | Inhibition of self-renewal capacity in stem-like side-population cells of human NCI-H1650 cells assessed as reduction in number of spheres at 1 to 20 uM incubated for 10 days by sphere formation assay | Homo sapiens | 8 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
5. | ALA4419957 | F | Cytotoxicity in human NCI-H1650 cells assessed as reduction in cell viability at 0.5 to 20 uM incubated for 72 hrs by MTT assay | Homo sapiens | 3 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
6. | ALA4419958 | F | Cytotoxicity in human A549 cells assessed as reduction in cell viability at 0.5 to 20 uM incubated for 72 hrs by MTT assay | Homo sapiens | 3 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
7. | ALA4419963 | B | Inhibition of YAP1 in human NCI-H1650 cells assessed as reduction in Sox2 protein expression at 5 uM by luciferase reporter gene assay | Homo sapiens | 2 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
8. | ALA4419964 | F | Inhibition of self-renewal capacity in stem-like side-population cells of human NCI-H1650 cells assessed as reduction in number of spheres at 5 uM incubated for 10 days by sphere formation assay relative to control | Homo sapiens | 2 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
9. | ALA4419965 | F | Cytotoxicity in human NCI-H1703 cells assessed as reduction in cell viability at 0.5 to 20 uM incubated for 96 hrs by MTT assay | Homo sapiens | 3 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
10. | ALA4419966 | F | Cytotoxicity in human NCI-H226 cells assessed as reduction in cell viability at 0.5 to 20 uM incubated for 96 hrs by MTT assay | Homo sapiens | 3 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
11. | ALA4419969 | F | Inhibition of adherence-independent cell growth in human NCI-H1650 cells at 5 uM incubated for 33 days | Homo sapiens | 5 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
12. | ALA4419970 | F | Inhibition of adherence-independent cell growth in human NCI-H1650 cells at 10 uM incubated for 33 days | Homo sapiens | 5 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
13. | ALA4419973 | F | Inhibition of self-renewal capacity in cisplatin insensitive stem-like side-population cells of human NCI-H1650 cells assessed as reduction in number of spheres at 2 uM incubated for 5 days after 7 days cisplatin exposure by sphere formation assay | Homo sapiens | 2 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
14. | ALA4419974 | F | Inhibition of self-renewal capacity in methotrexate insensitive stem-like side-population cells of human NCI-H146 cells assessed as reduction in number of spheres at 2 uM incubated for 3 days after 7 days methotrexate exposure by sphere formation assay | Homo sapiens | 6 | ALA4419178 | assay format | Patent Bioactivity Data | |
15. | ALA4419975 | F | Cytotoxicity in erlotinib-resistant human HCC827 cells assessed as reduction in cell viability at 1 to 20 uM by MTT assay | Homo sapiens | 3 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
16. | ALA4419976 | F | Cytotoxicity in gefitinib resistant human PC9 cells assessed as reduction in cell viability at 1 to 20 uM by MTT assay | Homo sapiens | 3 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
17. | ALA4419977 | F | Cytotoxicity in gefitinib and erlotinib resistant human NCI-H1975 cells assessed as reduction in cell viability at 1 to 10 uM incubated for 72 hrs by MTT assay | Homo sapiens | 5 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
18. | ALA4419978 | B | Inhibition of YAP1 in human NCI-H1650 cells assessed as suppression of Sox2 mRNA expression at 5 to 10 uM incubated for 72 hrs by RT-PCR method | Homo sapiens | 5 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
19. | ALA4419979 | B | Inhibition of YAP1 in human NCI-H1703 cells assessed as suppression of Sox2 mRNA expression at 5 to 10 uM incubated for 72 hrs by RT-PCR method | Homo sapiens | 5 | ALA4419178 | cell-based format | Patent Bioactivity Data | |
20. | ALA4419980 | B | Inhibition of YAP1 in human NCI-H146 cells assessed as suppression of Sox2 mRNA expression at 5 to 10 uM incubated for 72 hrs by RT-PCR method | Homo sapiens | 5 | ALA4419178 | cell-based format | Patent Bioactivity Data |